… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … 1/2 clinical trial of QR-421a, an investigational RNAtherapy. The Stellar trial is a randomized, single ascending …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … allowing us to advance this important investigational therapy for all patients with Usher syndrome and nsRP due to …
… at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting … to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … s epofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … were presented at the Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Presentation title: A different type of genetic therapy: correcting a defective gene using antisense …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … followed by a live Q&A session. Session: Stem cells/gene therapy/transplantation Date: May 6, 2021 at 5:15pm EDT …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … QR-421a QR-421a is a first-in-class investigational RNAtherapy designed to address the underlying cause of vision …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … QR-421a QR-421a is a first-in-class investigational RNAtherapy designed to address the underlying cause of vision …